Q4 2022 Newsletter – Deuterated Metabolites
December 2, 2022 4:41 pm Leave your thoughtsHypha’s Q4 2022 newsletter – synthesis of deuterated metabolites In our Q4 2022 newsletter we look at how Hypha make...
View Article
Hypha’s Q4 2022 newsletter – synthesis of deuterated metabolites In our Q4 2022 newsletter we look at how Hypha make...
View Article
AhR activators – friend or foe? A very usual metabolite, a very unusual pharmacological target, and an unexpected serious adverse...
View Article
Metabolism of covalent drugs: Stories from a resurgent field By Samuel Coe With the successful launch of Amgen’s targeted KRAS-blocking...
View Article
Hypha’s Q3 2022 newsletter – gut metabolites and unexpected conjugates In Hypha’s Q3 2022 newsletter we feature our new gut...
View Article
Bioisosteres that influence metabolism By Samuel Coe The majority of reviews on the application of bioisosteres are focused on effects...
View Article
Hypha’s Q2 2022 newsletter – GSH conjugates using PolyCYPs enzymes, metabolite purification case studies, and late-stage oxidation kits In Hypha’s...
View Article
Metabolism of t-butyl groups in drugs: t for trouble? By Julia Shanu-Wilson The tert-butyl group is a common group present...
View Article
Orphan CYPs – finding a home in personalised medicine By Samuel Coe Cytochrome P450 enzymes (CYPs) are responsible for the...
View Article
The underappreciated hydroxyl in drug discovery By Rob Young Here we explore some of the potential impacts of hydroxyl groups...
View Article
Q1 2022 Newsletter – API degradation products and steroid metabolism Our new service for accessing API degradation products and impurities...
View Article